VENTURE CAPITAL POST

Pfizer and AstraZeneca have announced massive investments in France totaling nearly $1 billion.

Pfizer has agreed to settle over 10,000 lawsuits concerning the alleged connection between its product, Zantac, and cancer.

Pfizer has agreed to settle over 10,000 lawsuits concerning its Zantac heartburn medication after it was found that a cancer risk was not disclosed.

A recent study conducted by the Centers for Disease Control and Prevention (CDC) has revealed that there is no link between COVID-19 vaccines and cardiac death in younger adults.

Pfizer is shifting its focus from COVID-related products to cancer drugs.

The cancer therapy was revealed during the Innovation Day event to engage investors and strengthen its position in cancer research and treatment.

Pfizer has agreed to pay $93 million to resolve antitrust claims by wholesale drug distributors accusing the pharmaceutical giant of conspiring with India's Ranbaxy Laboratories to delay the sales of cheaper versions of the cholesterol drug Lipitor.

Several major drug companies, including Pfizer, Sanofi, and Takeda Pharmaceutical, are gearing up to implement price hikes on over 500 drugs in the United States in early January.

Pharmaceutical giant Pfizer said it is set to finalize its $43 billion acquisition of cancer drugmaker Seagen this week.

The company called off the acquisition of Allergan after the U.S. Treasury issued the rule preventing the deal. Nevertheless, Chief Executive Officer Ian Read still has the investors support.

Pfizer and Allergan will have to scrap the merger deal following the new regulation from Treasury Department to stop the U.S. company moving overseas.

Pfizer, a US-based drug company, is said to dismiss its merger deal with Allergan. The US drugmaker wants to quit from the $160 billion merger deal since Washington authorities set new rules, making corporate inversions harder.

Pfizer said that net compensation of chief executive officer Ian Read declined 23% in 2015 driven by a drop in stock awards. The chief's net compensation amounted to $18 million in 2015.

Pfizer and other pharmaceutical companies still increase its drugs price in U.S. despite criticism. Mounting objection from politicans and lawmakers is unable to stop market power of companies in the multi-billion dollar phamaceutical industry.

Pfizer today confirmed that the company has increased the price of some of its drugs although it was not revealed how many drugs are involved with the price hike. According to a data by Wolters Kluwer which revealed that more than 100 types of drugs has been increased in its price starting on January 1st.